PMID- 32724321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Effectiveness and Safety of Panax ginseng Extract on Hepatic Dysfunction: A 
      Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
PG  - 2689565
LID - 10.1155/2020/2689565 [doi]
LID - 2689565
AB  - BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of 
      Panax ginseng extract (GS-KG9) in the treatment of hepatic dysfunction. METHODS: 
      A randomized, double-blind, placebo-controlled clinical trial was conducted from 
      December 2017 to January 2019. The trial included 60 subjects between the ages of 
      19 and 70 who had higher alanine transaminase (ALT) levels than the normal upper 
      limit. The subjects were randomly divided into two groups: GS-KG9 (n = 30) and 
      placebo (n = 30). The former was administered three GS-KG9 capsules (3 g/day) and 
      the latter three placebo capsules (3 g/day) twice each day orally after meals in 
      the morning and evening for 12 weeks. The primary goal was to observe the changes 
      in ALT and gamma-glutamyl transferase (GGT) levels. The safety of the treatment 
      was assessed and adverse events (AEs) were recorded. RESULTS: Out of 60 subjects, 
      nine were excluded from the efficacy analysis because they met the exclusion 
      criteria. Therefore, a total of 51 subjects were evaluated for the effectiveness 
      of the treatment (26 in the GS-KG9 group and 25 in the placebo group). After 12 
      weeks of treatment, the ALT levels were significantly reduced in the GS-KG9 group 
      compared to the placebo group (p=0.009). The GGT level of the GS-KG9 group was 
      significantly lower than that of the placebo group (p=0.036). Mild AEs, such as 
      diarrhea, occurred during the study. There were no significant differences 
      between the two groups. CONCLUSION: The results of this trial suggest that GS-KG9 
      might be an effective and safe option for mild hepatic dysfunction. This trial is 
      registered with KCT0004080.
CI  - Copyright (c) 2020 Lei Shen et al.
FAU - Shen, Lei
AU  - Shen L
AD  - Department of Constitutional Medicine, College of Korean Medicine, Wonkwang 
      University, Iksan 54538, Republic of Korea.
FAU - Gwak, Si Ra
AU  - Gwak SR
AD  - Department of Constitutional Medicine, College of Korean Medicine, Wonkwang 
      University, Iksan 54538, Republic of Korea.
FAU - Joo, Jong Cheon
AU  - Joo JC
AD  - Department of Constitutional Medicine, College of Korean Medicine, Wonkwang 
      University, Iksan 54538, Republic of Korea.
FAU - Song, Bong Keun
AU  - Song BK
AD  - Department of Internal Medicine, College of Korean Medicine, Wonkwang University, 
      Gwangju 51729, Republic of Korea.
FAU - Cha, Seon Woo
AU  - Cha SW
AD  - International Ginseng and Herb Research Institute, Geumsan 32724, Republic of 
      Korea.
FAU - Song, Young Uk
AU  - Song YU
AD  - Daedong Korea Ginseng Co., Ltd., Geumsan 32718, Republic of Korea.
FAU - Pyo, Mi Kyung
AU  - Pyo MK
AUID- ORCID: 0000-0001-9229-3282
AD  - International Ginseng and Herb Research Institute, Geumsan 32724, Republic of 
      Korea.
FAU - Park, Soo Jung
AU  - Park SJ
AUID- ORCID: 0000-0001-8191-4290
AD  - Department of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk 
      University, Jeonju 55338, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7381953
COIS- The authors declare that there are no conflicts of interest regarding the 
      publication of this paper.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
PMCR- 2020/07/16
CRDT- 2020/07/30 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
PHST- 2020/07/16 00:00 [pmc-release]
AID - 10.1155/2020/2689565 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Jul 16;2020:2689565. doi: 
      10.1155/2020/2689565. eCollection 2020.